This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Aurobindo moves to dismiss Walmart's US antitrust claims over generic drugs

( October 22, 2025, 17:49 GMT | Official Statement) -- MLex Summary: Aurobindo moved to dismiss Walmart's US antitrust claims over its supposed involvement in a conspiracy to fix the prices of generic drugs, arguing that the retailer's amended complaint repeats deficient pleadings and fails again to show that Aurobindo participated in a conspiracy. Walmart brings claims as to Aurobindo's MAS-IR, Combivir and Oxy/Apap drugs, yet no non-conclusory allegations over anticompetitive conduct that would provide a tie to any conspiracy, Aurobindo said in its motion to dismiss filed to the Eastern District of Pennsylvania.See attached document....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections